DXCM vs WST: stock comparison and AI forecast
Dexcom Inc (DXCM) and West Pharmaceutical Services Inc (WST) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
DXCM Dexcom Inc
- Price
- $88.48 +46.6% · 6M
- Market Cap
- $31.50B
- P/E Ratio
- 30.7x
- Size
- large-cap
- AI Forecast
WST West Pharmaceutical Services Inc
- Price
- $392.48 +21.9% · 6M
- Market Cap
- $27.34B
- P/E Ratio
- 44.1x
- Size
- large-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Six-month price performance
Closing prices rebased to 100 at the start of the window.
Key facts
- DXCM is 1.2 times larger than WST by market capitalization ($31.50B against $27.34B).
- DXCM trades at 30.7 times trailing earnings, WST at 44.0 times.
- Over the last six months DXCM returned +46.6% and WST +21.9%.
- DXCM turns 19.4% of its revenue into net income, against 18.8% for WST.
- DXCM carries 1.46 times debt per unit of equity, against 0.37 times for WST.
- WST yields 0.23% in dividends; DXCM pays none.
- Both companies share the SEC industry classification Surgical & Medical Instruments & Apparatus.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | DXCM | WST |
|---|---|---|
| Market Cap | $31.50B | $27.34B |
| P/E Ratio | 30.71x | 44.05x |
| P/B Ratio | 12.42x | 9.21x |
| Dividend Yield | – | 0.23% |
| EPS | $2.75 | $8.91 |
| Book Value/Share | $6.80 | $42.61 |
| Revenue/Share | $13.69 | $48.76 |
| FCF/Share | $2.94 | $6.51 |
Profitability & Margins
| Metric | DXCM | WST |
|---|---|---|
| ROE | 39.1% | 21.5% |
| ROA | 15.9% | 15.7% |
| ROIC | 30.7% | 22.8% |
| Gross Margin | 63.4% | 37.6% |
| Operating Margin | 24.0% | 23.0% |
| Net Margin | 19.4% | 18.8% |
| EBT Margin | 24.7% | 23.2% |
| Tax Rate | 21.5% | 21.3% |
Financial Health
| Metric | DXCM | WST |
|---|---|---|
| Current Ratio | 1.74x | 2.82x |
| Quick Ratio | 1.40x | 2.10x |
| D/E Ratio | 1.46x | 0.37x |
| Financial Leverage | 2.46x | 1.37x |
| Interest Coverage | 155.8x | 10.4x |
| Working Capital | $1.66B | $1.17B |
Cash Flow
| Metric | DXCM | WST |
|---|---|---|
| Operating Cash Flow | $1.41B | $654M |
| Free Cash Flow | $1.10B | $453M |
| Capital Spending | -$316M | -$201M |
| OCF Growth YoY | -2.3% | -5.7% |
| FCF Growth YoY | 3.4% | 19.6% |
| FCF/Sales | 21.5% | 13.3% |
| CapEx/Sales | 6.2% | 5.9% |
Operational Efficiency
| Metric | DXCM | WST |
|---|---|---|
| Asset Turnover | 0.82x | 0.84x |
| Receivables Turnover | 4.3x | 4.5x |
| Inventory Turnover | 2.4x | 4.6x |
| Fixed Assets Turnover | 3.3x | 2.0x |
| Days Sales Outstanding | 85 days | 80 days |
| Days Inventory | 151 days | 80 days |
| Payables Period | 404 days | 43 days |
| Cash Conversion Cycle | -168 days | 117 days |
Income Statement
| Metric | DXCM | WST |
|---|---|---|
| Total Revenue | $5.10B | $3.40B |
| Operating Income | $1.22B | $780M |
| Net Income | $991M | $639M |
| R&D Expense | $608M | $76M |
| SG&A Expense | $1.41B | $437M |
| Cost of Goods Sold | $1.87B | $2.12B |
Dividend & Shareholder Information
| Metric | DXCM | WST |
|---|---|---|
| Dividends Per Share | – | $0.90 |
| Payout Ratio | – | 10.1% |
| Shares Outstanding | 373M | 70M |
| Net Income Growth | 37.5% | 29.9% |
| EPS Growth | 54.5% | 32.0% |
DXCM vs WST: stock comparison and AI forecast
Which is bigger, DXCM or WST?
DXCM is 1.2 times larger than WST by market capitalization ($31.50B against $27.34B).
Which is cheaper on earnings, DXCM or WST?
DXCM trades at 30.7 times trailing earnings, WST at 44.0 times.
Which stock performed better over the last six months, DXCM or WST?
Over the last six months DXCM returned +46.6% and WST +21.9%.
Which one does Intratio's AI model rank higher, DXCM or WST?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.